Researchers, including a team from Cornell, have discovered that the FDA-approved drug trametinib can effectively treat oral squamous cell carcinomas in dogs, the most common oral cancer affecting canines. This drug, known for its use in human melanoma treatment, demonstrates safety and cost-effectiveness in dogs. Clinical trials showed remarkable results, with one dog's tumor nearly vanishing in weeks. This breakthrough offers a new option for pet owners facing the challenges of disfiguring surgeries and advanced cancer, making it an important development in veterinary oncology.
"It's a super exciting clinical tool that we now have available... We are already getting calls and emails from colleagues and from dog owners from all over the world."
"I've never seen results like that in mice before... being on a project that made it to the clinic and seeing the tumor nearly vanish in a couple of weeks was delightfully surprising."
Collection
[
|
...
]